Fourth Quarter & Full Year 2022 Financial & Business Update
Progressing Development of TIVDAK in Cervical Cancer and Other
Solid Tumor Indications
innovaTV 205 combination data in 1L+ r/mCC
presented at ASCO 20221 demonstrated
encouraging anti-tumor activity
2L/3L TV
Parameters
1L TV +
carbo
(N=33)²
1L TV +
Keytruda
(N=32)³
+
Confirmed
response rate,
54.5
40.6
38.2
%
innovaTV 301 in 2L+ r/mCC intended to serve as
basis for global regulatory submissions
Enrollment completion expected in 1Q 2023
• Topline data expected by YE23
Keytruda
(N=34)4
tivdak
tisotumab vedotin-tftv
for injection 40 mg
Now NCCN preferred
regimen for the treatment
of 2L+ recurrent or
metastatic cervical
innovaTV 207 head & neck cancer data
planned for 1H 2023
• Data update to include Q2W dose regimen
CR, %
12.1
15.6
8.8
PR, %
42.4
25.0
29.4
Median duration
of response
(DOR), months
8.6
NR5
14.0
cancer6
innovaTV 205 1L+ r/mCC data planned for 2H 2023
Investigating triplet and quad regimens with chemo, Keytruda +/-
bevacizumab, replacing taxanes
1 Lorusso, et al, ASCO 2022; combinations not currently approved for use; 2 median follow-up of 14.6;months; 3 median follow-up of 18.8 months; 4 median follow-up of 15.0 months;
verification and description of clinical benefit in confirmatory trials; refer to TIVDAK USPI for complete safety information, including a BOXED WARNING for Ocular Toxicity
Seagen Collaboration with Genmab "Not reached ; 6 NCCN now lists TIVDAK as a Category 2A preferred regimen; approved under accelerated approval; continued approval for this indication may be contingent upon
25View entire presentation